(Q44741629)

5 December 2017

Glimepiride pharmacokinetics in obese versus non-obese diabetic patients (English)

1 reference

5 December 2017

0 references

1 reference

Umesh A Shukla

1

1 reference

5 December 2017

Eric M Chi

series ordinal

2

1 reference

5 December 2017

Karl-Heinz Lehr

series ordinal

3

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

Annals of Pharmacotherapy

5 December 2017

1 reference

5 December 2017

38

1 reference

5 December 2017

1

1 reference

5 December 2017

30-35

1 reference

5 December 2017

Sulfonylureas in NIDDM.

1 reference

Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.

21 January 2018

1 reference

Clinical profile of glimepiride

21 January 2018

1 reference

An overview of the safety and tolerance of glimepiride

21 January 2018

1 reference

Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group.

21 January 2018

1 reference

Impact of dosage frequency on patient compliance.

21 January 2018

1 reference

Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1C397

1 reference

5 December 2017

1 reference